The use of cerebroprotein hydrolysate in dementia: A case series of 25 cases seen in a tertiary general hospital
Autor: | Avinash Desousa, Sushma Sonavane, Nilesh Shah, Mosam Phirke, Anup Bharati |
---|---|
Rok vydání: | 2014 |
Předmět: |
medicine.medical_specialty
Pediatrics lcsh:RC435-571 cerebrolysin lcsh:Geriatrics Adenbrook′s cognitive examination-revised Hydrolysate Mini Mental Status Examination chemistry.chemical_compound lcsh:Psychiatry Chart review mental disorders medicine Dementia General Hospital Psychiatry General hospital Psychiatry business.industry medicine.disease lcsh:RC952-954.6 chemistry Cerebrolysin mini mental status examination cerebroprotein hydrolysate Cognitive Assessment System business dementia |
Zdroj: | Journal of Geriatric Mental Health, Vol 1, Iss 2, Pp 106-109 (2014) |
ISSN: | 2348-9995 |
DOI: | 10.4103/2348-9995.152431 |
Popis: | Background: Cerebroprotein hydrolysate (Cerebrolysin) is a pharmacological and neurotrophic agent that has been used widely in the management of various forms of dementia. Purpose: The present paper presents a retrospective chart review of 25 patients with dementia visiting a tertiary general hospital psychiatry unit who received cerebroprotein hydrolysate as an add on treatment for dementia. Materials and Methods: Twenty-five patients were administered 20 doses of cerebroprotein hydrolysate intravenously at a dose of 60 mg in 250 ml normal saline over 1-2 h after a test dose on 20 consecutive days. The cognitive assessment was done before the first injection and after the last dose using the Adenbrook′s Cognitive Examination-Revised (ACER) and the Mini Mental Status Examination (MMSE). Results: There was significant improvement in scores on the ACER and MMSE, although the final scores remained in the dementia range. None of the patients experienced any major side effects. Conclusions: Cerebroprotein thus is a useful pharmacological option in the management of dementia and warrants further study and exploration. |
Databáze: | OpenAIRE |
Externí odkaz: |